Joanna Tzoulaki is Professor of Chronic Disease Epidemiology in the School of Public Health at Imperial College London. Joanna obtained a PhD at the University of Edinburgh on the epidemiology of peripheral arterial disease.
Her research aims to improve the understanding of chronic disease aetiology and to improve disease prevention through better risk stratification strategies. She has worked with genetic and other molecular data to identify disease biomarkers and biological pathways underlying diseases such as cardiovascular and neurodegenerative diseases. She is leading the Population Health theme of the BHF Centre of Excellence at Imperial and is collaborating with several UK and US partners leading consortia funded by the European Commission and US National Institute of Health. Joanna is also co-leading the NIHR BRC theme on Multiple Coexisting Conditions (multimorbidity). She has contributed as expert and advisor in several organisations and committees including the European Food and Safety Authority and was a member of the UK Biobank Enhancement Subgroup which worked on the enhanced phenotyping of UK Biobank participants. She is also committed to widening opportunities in academic careers having led the School of Public Health ATHENA SWAN (Scientific Women’s Academic Network) application and the Opportunities Committee.
et al., 2023, A second update on mapping the human genetic architecture of COVID-19, Nature, Vol:621, ISSN:0028-0836, Pages:E7-E26
et al., 2023, Untargeted metabolomic analysis investigating links between unprocessed red meat intake and markers of inflammation., Am J Clin Nutr
et al., 2023, GWAS of random glucose in 476,326 individuals provide insights into diabetes pathophysiology, complications and treatment stratification., Nat Genet, Vol:55, Pages:1448-1461
et al., 2023, Metabolomic Profiling of Cholesterol Efflux Capacity in a Multiethnic Population: Insights From MESA., Arterioscler Thromb Vasc Biol
et al., 2023, The cardiovascular efficacy of lipid-lowering drug targets is not entirely explained by apolipoprotein B reduction: Mendelian randomization evidence, Circulation: Genomic and Precision Medicine, ISSN:2574-8300